Playback speed
10 seconds
ESMO 2023 Insights: "Results From the MEDISARC Phase II Study of Durvalumab & Tremelimumab Compared to Doxorubicin in Patients With Advanced/Metastatic Soft Tissue Sarcoma"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Viktor Grünwald
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Viktor Grünwald
132 views
October 25, 2023
Login to view comments.
Click here to Login